Functional Connectivity in the Basal Ganglia Network Differentiates PD Patients from Controls
Authors
Affiliations
Objective: To examine functional connectivity within the basal ganglia network (BGN) in a group of cognitively normal patients with early Parkinson disease (PD) on and off medication compared to age- and sex-matched healthy controls (HC), and to validate the findings in a separate cohort of participants with PD.
Methods: Participants were scanned with resting-state fMRI (RS-fMRI) at 3T field strength. Resting-state networks were isolated using independent component analysis. A BGN template was derived from 80 elderly HC participants. BGN maps were compared between 19 patients with PD on and off medication in the discovery group and 19 age- and sex-matched controls to identify a threshold for optimal group separation. The threshold was applied to 13 patients with PD (including 5 drug-naive) in the validation group to establish reproducibility of findings.
Results: Participants with PD showed reduced functional connectivity with the BGN in a wide range of areas. Administration of medication significantly improved connectivity. Average BGN connectivity differentiated participants with PD from controls with 100% sensitivity and 89.5% specificity. The connectivity threshold was tested on the validation cohort and achieved 85% accuracy.
Conclusions: We demonstrate that resting functional connectivity, measured with MRI using an observer-independent method, is reproducibly reduced in the BGN in cognitively intact patients with PD, and increases upon administration of dopaminergic medication. Our results hold promise for RS-fMRI connectivity as a biomarker in early PD.
Classification Of Evidence: This study provides Class III evidence that average connectivity in the BGN as measured by RS-fMRI distinguishes patients with PD from age- and sex-matched controls.
Liu P, Lin T, Fischer H, Feifel D, Ebner N Neuropharmacology. 2024; 260():110130.
PMID: 39182569 PMC: 11752694. DOI: 10.1016/j.neuropharm.2024.110130.
Why so slow? Models of parkinsonian bradykinesia.
Williams D Nat Rev Neurosci. 2024; 25(8):573-586.
PMID: 38937655 DOI: 10.1038/s41583-024-00830-0.
Pan Y, Bi C, Kochunov P, Shardell M, Smith J, McCoy R bioRxiv. 2024; .
PMID: 38798606 PMC: 11118564. DOI: 10.1101/2024.05.17.594743.
How should we be using biomarkers in trials of disease modification in Parkinson's disease?.
Vijiaratnam N, Foltynie T Brain. 2023; 146(12):4845-4869.
PMID: 37536279 PMC: 10690028. DOI: 10.1093/brain/awad265.
Meulenberg C, Rehfeld K, Jovanovic S, Marusic U Front Aging Neurosci. 2023; 15:1188855.
PMID: 37434737 PMC: 10331838. DOI: 10.3389/fnagi.2023.1188855.